Probing expert opinions on the future of kidney replacement therapies

Future Use of AI in Diagnostic Medicine: 2-Wave Cross-Sectional Survey Study

BACKGROUND

The rapid evolution of artificial intelligence (AI) presents transformative potential for diagnostic medicine, offering opportunities to enhance diagnostic accuracy, reduce costs, and improve patient outcomes.

OBJECTIVE

This study aimed to assess the expected future impact of AI on diagnostic medicine by comparing global researchers' expectations using 2 cross-sectional surveys.

METHODS

The surveys were conducted in September 2020 and February 2023. Each survey captured a 10-year projection horizon, gathering insights from >3700 researchers with expertise in AI and diagnostic medicine from all over the world. The survey sought to understand the perceived benefits, integration challenges, and evolving attitudes toward AI use in diagnostic settings.

RESULTS

Results indicated a strong expectation among researchers that AI will substantially influence diagnostic medicine within the next decade. Key anticipated benefits include enhanced diagnostic reliability, reduced screening costs, improved patient care, and decreased physician workload, addressing the growing demand for diagnostic services outpacing the supply of medical professionals. Specifically, x-ray diagnosis, heart rhythm interpretation, and skin malignancy detection were identified as the diagnostic tools most likely to be integrated with AI technologies due to their maturity and existing AI applications. The surveys highlighted the growing optimism regarding AI's ability to transform traditional diagnostic pathways and enhance clinical decision-making processes. Furthermore, the study identified barriers to the integration of AI in diagnostic medicine. The primary challenges cited were the difficulties of embedding AI within existing clinical workflows, ethical and regulatory concerns, and data privacy issues. Respondents emphasized uncertainties around legal responsibility and accountability for AI-supported clinical decisions, data protection challenges, and the need for robust regulatory frameworks to ensure safe AI deployment. Ethical concerns, particularly those related to algorithmic transparency and bias, were noted as increasingly critical, reflecting a heightened awareness of the potential risks associated with AI adoption in clinical settings. Differences between the 2 survey waves indicated a growing focus on ethical and regulatory issues, suggesting an evolving recognition of these challenges over time.

CONCLUSIONS

Despite these barriers, there was notable consistency in researchers' expectations across the 2 survey periods, indicating a stable and sustained outlook on AI's transformative potential in diagnostic medicine. The findings show the need for interdisciplinary collaboration among clinicians, AI developers, and regulators to address ethical and practical challenges while maximizing AI's benefits. This study offers insights into the projected trajectory of AI in diagnostic medicine, guiding stakeholders, including health care providers, policy makers, and technology developers, on navigating the opportunities and challenges of AI integration.

The Future of Technology-Based Kidney Replacement Therapies: An Update on Portable, Wearable, and Implantable Artificial Kidneys

Worldwide, the number of people who need lifesaving kidney replacement therapy (KRT) steadily increases, but approximately two thirds of them lack access to KRT and therefore die. Access to KRT depends on economic, social, infrastructural, ecological, and political factors. Current KRTs include kidney transplant, peritoneal dialysis, and hemodialysis. The field of xenotransplantation has been opening promising new perspectives recently but needs improvement. Unfortunately, not all patients are suitable for transplant. Peritoneal dialysis and hemodialysis will remain important KRTs, but they are expensive and strongly dependent on infrastructure, with few fundamental changes since the 1980s. The KRT field might learn from the "African mobile phone revolution" that beat infrastructural limitations, lowered costs, and increased access. We provide a nonexhaustive overview of promising ways to increase the mobility of technology-based KRTs by dialysate regeneration, chip-based nanoporous filters, bioreactor-enabling technologies, and using the gut as a "third kidney." In 2018, the Kidney Health Initiative published a road map for innovative KRTs composed by leading innovators, but the pace of innovation is slower than was targeted. Ambitious political statements about realizing this road map can only succeed if the granted funding matches the targeted time scale. Patient-centered international "coopetition" (ie, the act of cooperation between competing entities) seems to offer the quickest pathway to success.

Transportable, portable, wearable and (partially) implantable haemodialysis systems: comparison of technologies and readiness levels

Background

Dialysis modalities and their various treatment schedules result from complex compromises ('trade-offs') between medical, financial, technological, ergonomic, and ecological factors. This study targets summarizing the mutual influence of these trade-offs on (trans)portable, wearable, or even (partially) implantable haemodialysis (HD) systems, identify what systems are in development, and how they might improve quality of life (QoL) for patients with kidney failure.

Methods

HD as defined by international standard IEC 60601-2-16 was applied on a PUBMED database query regarding (trans)portable, wearable, and (partly) implantable HD systems. Out of 159 search results, 24 were included and scanned for specific HD devices and/or HD systems in development. Additional information about weight, size, and development status was collected by the internet and/or contacting manufacturers. International airplane hand baggage criteria formed the boundary between transportable and portable. Technology readiness levels (TRLs) were assigned by combining TRL scales from the European Union and NATO medical staff.

Results

The query revealed 13 devices/projects: seven transportable (six TRL9, one TRL5); two portable (one TRL6-7, one TRL4); two wearable (one TRL6, one frozen); and two partly implantable (one TRL4-5, one TRL2-3).

Discussion

Three main categories of technical approaches were distinguished: single-pass, dialysate regenerating, and implantable HD filter with extracorporeal dialysate regeneration (in climbing order of mobility).

Conclusions

Kidneys facilitate mobility by excreting strongly concentrated waste solutes with minimal water loss. Mimicking this kidney function can increase HD system mobility. Dialysate-regenerating HD systems are enablers for portability/wearability and, combined with durable implantable HD filters (once available), they may enable HD without needles or intravascular catheters. However, lack of funding severely hampers progress.

Future of Artificial Intelligence Applications in Cancer Care: A Global Cross-Sectional Survey of Researchers

Cancer significantly contributes to global mortality, with 9.3 million annual deaths. To alleviate this burden, the utilization of artificial intelligence (AI) applications has been proposed in various domains of oncology. However, the potential applications of AI and the barriers to its widespread adoption remain unclear. This study aimed to address this gap by conducting a cross-sectional, global, web-based survey of over 1000 AI and cancer researchers. The results indicated that most respondents believed AI would positively impact cancer grading and classification, follow-up services, and diagnostic accuracy. Despite these benefits, several limitations were identified, including difficulties incorporating AI into clinical practice and the lack of standardization in cancer health data. These limitations pose significant challenges, particularly regarding testing, validation, certification, and auditing AI algorithms and systems. The results of this study provide valuable insights for informed decision-making for stakeholders involved in AI and cancer research and development, including individual researchers and research funding agencies.

Development of Cell Therapies for Renal Disease and Regenerative Medicine

The incidence of renal disease is gradually increasing worldwide, and this condition has become a major public health problem because it is a trigger for many other chronic diseases. Cell therapies using multipotent mesenchymal stromal cells, hematopoietic stem cells, macrophages, and other cell types have been used to induce regeneration and provide a cure for acute and chronic kidney disease in experimental models. This review describes the advances in cell therapy protocols applied to acute and chronic kidney injuries and the attempts to apply these treatments in a clinical setting.

Wearable and implantable artificial kidney devices for end-stage kidney disease treatment-Current status and review

BACKGROUND

Chronic kidney disease (CKD) is a major cause of early death worldwide. By 2030, 14.5 million people will have end-stage kidney disease (ESKD, or CKD stage 5), yet only 5.4 million will receive kidney replacement therapy (KRT) due to economic, social, and political factors. Even for those who are offered KRT by various means of dialysis, the life expectancy remains far too low.

OBSERVATION

Researchers from different fields of artificial organs collaborate to overcome the challenges of creating products such as Wearable and/or Implantable Artificial Kidneys capable of providing long-term effective physiologic kidney functions such as removal of uremic toxins, electrolyte homeostasis, and fluid regulation. A focus should be to develop easily accessible, safe, and inexpensive KRT options that enable a good quality of life and will also be available for patients in less-developed regions of the world.

CONCLUSIONS

Hence, it is required to discuss some of the limits and burdens of transplantation and different techniques of dialysis, including those performed at home. Furthermore, hurdles must be considered and overcome to develop wearable and implantable artificial kidney devices that can help to improve the quality of life and life expectancy of patients with CKD.

Anticipating New Treatments for Cystic Fibrosis: A Global Survey of Researchers

Cystic fibrosis is a life-threatening disease that affects at least 100,000 people worldwide. It is caused by a defect in the cystic fibrosis transmembrane regulator (CFTR) gene and presently, 360 CFTR-causing mutations have been identified. Since the discovery of the CFTR gene, the expectation of developing treatments that can substantially increase the quality of life or even cure cystic fibrosis patients is growing. Yet, it is still uncertain today which developing treatments will be successful against cystic fibrosis. This study addresses this gap by assessing the opinions of over 524 cystic fibrosis researchers who participated in a global web-based survey. For most respondents, CFTR modulator therapies are the most likely to succeed in treating cystic fibrosis in the next 15 years, especially through the use of CFTR modulator combinations. Most respondents also believe that fixing or replacing the CFTR gene will lead to a cure for cystic fibrosis within 15 years, with CRISPR-Cas9 being the most likely genetic tool for this purpose.

Future of genetic therapies for rare genetic diseases: what to expect for the next 15 years?

Introduction

Rare genetic diseases affect millions of people worldwide. Most of them are caused by defective genes that impair quality of life and can lead to premature death. As genetic therapies aim to fix or replace defective genes, they are considered the most promising treatment for rare genetic diseases. Yet, as these therapies are still under development, it is still unclear whether they will be successful in treating these diseases. This study aims to address this gap by assessing researchers' opinions on the future of genetic therapies for the treatment of rare genetic diseases.

Methods

We conducted a global cross-sectional web-based survey of researchers who recently authored peer-reviewed articles related to rare genetic diseases.

Results

We assessed the opinions of 1430 researchers with high and good knowledge about genetic therapies for the treatment of rare genetic diseases. Overall, the respondents believed that genetic therapies would be the standard of care for rare genetic diseases before 2036, leading to cures after this period. CRISPR-Cas9 was considered the most likely approach to fixing or replacing defective genes in the next 15 years. The respondents with good knowledge believed that genetic therapies would only have long-lasting effects after 2036, while those with high knowledge were divided on this issue. The respondents with good knowledge on the subject believed that non-viral vectors are more likely to be successful in fixing or replacing defective genes in the next 15 years, while most of the respondents with high knowledge believed viral vectors would be more successful.

Conclusion

Overall, the researchers who participated in this study expect that in the future genetic therapies will greatly benefit the treatment of patients with rare genetic diseases.